US Approval Still Awaited: Nectar Lifesciences

PUBLISHED ON: June 1, 2016 | Duration: 8 min, 03 sec

   
loading..
Talking about earnings for the fourth quarter of 2015-16, Dinesh Dua, CEO and director of Nectar Lifesciences, says FY17 will be an important year for the company. Nectar Lifesciences awaits approval of drugs in the US which will be a big growth trigger ahead, he adds.
ALSO WATCH
गोशाला में कॉरपोरेट फ़ंडिंग

................................ Advertisement ................................

................................ Advertisement ................................

................................ Advertisement ................................